TICK-BORNE ENCEPHALITIS (TBE) VACCINE

Katherine Poehling, MD, MPH
Chair, ACIP TBE Vaccine Work Group
February 23, 2022
Background

- Food and Drug Administration (FDA) approved a TBE vaccine (manufactured by Pfizer as TICOVAC) in August 2021
- No TBE vaccine previously licensed in the United States
- No existing ACIP TBE vaccine recommendations
- TBE Vaccine Work Group formed in September 2020 to discuss use of TBE vaccine in U.S. persons traveling abroad and laboratory workers
# TBE Vaccine Work Group members and participants

## ACIP
- **Chair:** Katherine Poehling
  - **ACIP liaisons:** David Shlim, ISTM
  - **Technical advisors (cont’d):** Steven Schofield, CATMAT
  - **CDC participants (cont’d):** Stacey Martin, DVBD

- **Wilbur Chen**
  - **ACIP liaisons:** Mark Sawyer, AAP
  - **Technical advisors (cont’d):** Bryan Schumacher, DOD
    - **CDC participants (cont’d):** Michael McNeil, DHQP
  - **CDC participants:** Mary Wilson, Univ Calif SFO
    - **Consultant:** Rebecca Morgan

## CDC Lead
- **Susan Hills, DVBD**
  - **Technical advisors:** Alan Barrett, Univ Texas Galveston
    - **CDC participants:** Grace Appiah, DGMQ
  - **Lin Chen, Mount Auburn Hosp**

## Ex Officio
- **Rodolfo (Rudy) Alarcon, NIH**
  - **Technical advisors:** Anthony Marfin, PATH
    - **ACIP Secretariat:** Doug Campos-Outcalt, Consultant
  - **Bruce McClennathan, DOD**
  - **ACIP Secretariat:** Susan Chu, GID
  - **Kayvon Modjarrad, DOD**
  - **ACIP Secretariat:** Caitlin Cossaboom, DHCPP
  - **ACIP Secretariat:** Melinda Wharton, NCIRD

---

**Note:** This list includes members and participants from various organizations involved in the TBE Vaccine Work Group, with representatives from the Advisory Committee on Immunization Practices (ACIP), CDC, and Ex Officio members from PATH and the National Institute of Health (NIH). It also highlights technical advisors and CDC participants involved in the decision-making process for vaccine recommendations.
Overview of previous Work Group presentations to ACIP

- October 2020
  - Background on TBE disease and vaccines
  - Summary of Pfizer’s TBE vaccine

- February 2021
  - TBE epidemiology in endemic areas
  - TBE among U.S. travelers and laboratory workers

- September 2021
  - Immunogenicity and safety of Pfizer’s TBE vaccine

- January 2022
  - Evidence to Recommendations framework
Overview of today’s session

- Brief review of TBE and TBE vaccine
- Review of considerations for use of TBE vaccine and proposed recommendations for laboratory workers
- Review of considerations for use of TBE vaccine and proposed recommendations for persons who travel abroad